The Asia-Pacific Pharmaceutical Compliance Congress and Best Practices Forum
The Asia-Pacific Pharmaceutical Compliance Congress and Best Practices Forum Highlights
Tim Ayers presented an overview on Advanced Issues in Global Transparency, Disclosure, Aggregate Spend and Sunshine during the Key Issues Overview/Mini Summit Preview at 4:30 PM on Tuesday, September 16, 2014. Tim spoke on Advanced Issues in Global Transparency, Disclosure, Aggregate Spend and Sunshine during Mini-Summit II at 1:15 PM, and Auditing Distributors for a Small or Mid-sized Company during Mini Summit XII at 4:45 PM on Wednesday, September 17, 2014.
Auditing Distributors for a Small or Mid-sized Company Discussion Points:
- What Issues are more Important to Audit
- Who Participates (GxP Issues or just Fraud)
- How many Layers do you Audit
The life sciences industry in Asia Pacific has been growing at breakneck speed. The law and regulations surrounding the industry have been increasing exponentially. Certainty and consistency in the application of these new laws, regulation and codes has been uneven. There has been intense regulatory enforcement focus on the industry by various Asian governments in order to create a more transparent environment and provide consistent guidelines. Accordingly, it is a particularly appropriate time for the Congress to return to China. The Congress will focus on the special regulatory and compliance concerns for pharmaceutical companies doing business in China.
For more information, please click here.